Trends in 5-Alpha Reductase Inhibitor Use Before and After the Food and Drug Administration Safety Warning

    Craig Labbate, Brittany Adamic, Pooja Talaty … Brian T. Helfand
    Studysummary After the FDA's 2011 warning about a potential prostate cancer risk with 5-alpha reductase inhibitors, this study observed a significant decrease in their prescriptions, notably a 49% drop among men with benign prostatic hyperplasia, while primary care providers reduced prescriptions by 60%.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on auajournals.org →
    Discuss this study in the Community →